2-pyrrolino-dox has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arencibia, JM; Bajo, AM; Chatzistamou, I; Krupa, M; Nagy, A; Schally, AV | 1 |
| Nagy, A; Schally, AV | 1 |
1 review(s) available for 2-pyrrolino-dox and Cancer of Ovary
| Article | Year |
|---|---|
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Endometrial Neoplasms; Epithelial Cells; Female; Gonadotropin-Releasing Hormone; Humans; Male; Ovarian Neoplasms; Prostatic Neoplasms; Pyrroles; Receptors, LHRH | 2005 |
1 other study(ies) available for 2-pyrrolino-dox and Cancer of Ovary
| Article | Year |
|---|---|
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Pyrroles; Receptor, ErbB-2; Receptors, LHRH; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; Tumor Cells, Cultured | 2002 |